NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 49,772 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 49,772 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $25.60, for a total transaction of $1,274,163.20. Following the transaction, the insider now directly owns 10,802,224 shares of the company’s stock, valued at approximately $276,536,934.40. This trade represents a 0.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total value of $640,614.68.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS traded up $0.28 during trading on Thursday, reaching $26.23. 354,639 shares of the company traded hands, compared to its average volume of 377,444. The firm has a 50 day simple moving average of $21.72 and a 200-day simple moving average of $19.09. NewAmsterdam Pharma has a 52-week low of $10.50 and a 52-week high of $27.29.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. Frazier Life Sciences Management L.P. lifted its holdings in NewAmsterdam Pharma by 5.1% in the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after acquiring an additional 628,251 shares during the period. Janus Henderson Group PLC increased its holdings in NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after buying an additional 520,772 shares during the last quarter. Decheng Capital LLC bought a new position in NewAmsterdam Pharma in the second quarter worth approximately $7,684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of NewAmsterdam Pharma by 1,231.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after acquiring an additional 221,305 shares during the last quarter. Finally, Millennium Management LLC lifted its position in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after purchasing an additional 217,902 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Scotiabank upped their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and an average price target of $36.20.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.